{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:14:31Z","timestamp":1794442471945,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460502"],"award-info":[{"award-number":["82460502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160545"],"award-info":[{"award-number":["82160545"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004880","name":"Xinjiang Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinsp.2025.100849","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T03:54:28Z","timestamp":1766030068000},"page":"100849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-2875","authenticated-orcid":false,"given":"Bihui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7988-4032","authenticated-orcid":false,"given":"Yulian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-2846","authenticated-orcid":false,"given":"Mingkai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8964-2135","authenticated-orcid":false,"given":"Manli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-7665","authenticated-orcid":false,"given":"Jianbing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1621-5903","authenticated-orcid":false,"given":"Zhifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clinsp.2025.100849_bib0001","first-page":"505","article-title":"Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus","volume":"71","author":"Castle","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100849_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100849_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003667","article-title":"Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"669","key":"10.1016\/j.clinsp.2025.100849_bib0004","doi-asserted-by":"crossref","first-page":"eabj1270","DOI":"10.1126\/scitranslmed.abj1270","article-title":"Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade","volume":"14","author":"Stanczak","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100849_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-022-01347-4","article-title":"Development of effective Siglec-9 antibodies against cancer","volume":"25","author":"Wang","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"26","key":"10.1016\/j.clinsp.2025.100849_bib0006","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100849_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007099","article-title":"Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinsp.2025.100849_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90","author":"Stanczak","year":"2023","journal-title":"Mol Aspects Med"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100849_bib0009","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.it.2020.02.001","article-title":"Sialoglycans and siglecs can shape the tumor immune microenvironment","volume":"41","author":"van de Wall","year":"2020","journal-title":"Trends Immunol"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100849_bib0010","doi-asserted-by":"crossref","first-page":"e1524","DOI":"10.1002\/cti2.1524","article-title":"Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling","volume":"13","author":"van Houtum","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.clinsp.2025.100849_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111771","article-title":"Siglec9 + tumor-associated macrophages predict prognosis and therapeutic vulnerability in patients with colon cancer","volume":"130","author":"Chang","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100849_bib0012","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.clinsp.2025.100849_bib0013","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100849_bib0014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-18-0505","article-title":"Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumor microenvironment","volume":"7","author":"Haas","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.clinsp.2025.100849_bib0015","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"20","key":"10.1016\/j.clinsp.2025.100849_bib0016","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.clinsp.2025.100849_bib0017","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.omtn.2021.03.017","article-title":"Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and transcriptional activities of ECs in CC","volume":"24","author":"Li","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"issue":"D1","key":"10.1016\/j.clinsp.2025.100849_bib0018","doi-asserted-by":"crossref","first-page":"D362","DOI":"10.1093\/nar\/gkw937","article-title":"The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible","volume":"45","author":"Szklarczyk","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100849_bib0019","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinsp.2025.100849_bib0020","article-title":"STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100849_bib0021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s40425-019-0593-1","article-title":"Carboplatin\/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors","volume":"7","author":"Domingos-Pereira","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.clinsp.2025.100849_bib0022","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/2326-6066.CIR-18-0166","article-title":"Nanoparticle conjugation of Human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice","volume":"6","author":"Galliverti","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clinsp.2025.100849_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102385","article-title":"Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials","volume":"106","author":"Monk","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100849_bib0024","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clinsp.2025.100849_bib0025","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-22-1280","article-title":"Efficacy and safety of the Anti-PD-L1 mAb Socazolimab for recurrent or metastatic cervical cancer: a phase I dose-escalation and expansion study","volume":"28","author":"An","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100849_bib0026","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"L\u00e4ubli","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clinsp.2025.100849_bib0027","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cbpa.2021.01.001","article-title":"Siglec and anti-Siglec therapies","volume":"62","author":"Murugesan","year":"2021","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100849_bib0028","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaci.2023.04.007","article-title":"Siglec-9 is an inhibitory receptor on human mast cells in vitro","volume":"152","author":"Miralda","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinsp.2025.100849_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.743515","article-title":"Siglec-9, a putative immune checkpoint marker for cancer progression across multiple cancer types","volume":"9","author":"Wu","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"705","key":"10.1016\/j.clinsp.2025.100849_bib0030","doi-asserted-by":"crossref","first-page":"eadf5302","DOI":"10.1126\/scitranslmed.adf5302","article-title":"Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma","volume":"15","author":"Schmassmann","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100849_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/2326-6066.CIR-19-0315","article-title":"Myeloid cells orchestrate systemic immunosuppression, impairing the efficacy of immunotherapy against HPV(+) cancers","volume":"8","author":"Galliverti","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.clinsp.2025.100849_bib0032","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/2159-8290.CD-25-0382","article-title":"HPV16-Expressing tumors release multiple IL-1 ligands to orchestrate systemic immunosuppression whose disruption enables efficacy of a therapeutic vaccine","volume":"15","author":"Lecointre","year":"2025","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.clinsp.2025.100849_bib0033","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1172\/JCI120612","article-title":"Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells","volume":"128","author":"Stanczak","year":"2018","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100849_bib0034","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41590-024-01776-2","article-title":"The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis","volume":"25","author":"He","year":"2024","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100849_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100849_bib0036","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response","volume":"4","author":"Mei","year":"2023","journal-title":"Nat Cancer"},{"issue":"48","key":"10.1016\/j.clinsp.2025.100849_bib0037","doi-asserted-by":"crossref","first-page":"33481","DOI":"10.1074\/jbc.M114.593129","article-title":"Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related siglecs","volume":"289","author":"L\u00e4ubli","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100849_bib0038","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s42003-020-01359-5","article-title":"Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype","volume":"3","author":"Beatson","year":"2020","journal-title":"Commun Biol"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100849_bib0039","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/cancers13092072","article-title":"Characterization of cell-bound CA125 on immune cell subtypes of ovarian cancer patients using a novel imaging platform","volume":"13","author":"Gonz\u00e1lez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100849_bib0040","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00262-022-03364-5","article-title":"LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma","volume":"72","author":"Zhao","year":"2023","journal-title":"Cancer Immunol Immunother"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:28:58Z","timestamp":1793964538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593225002674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S1807593225002674"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100849","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100849"}}